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Exacerbation of systemic lupus erythematosus in a patient with concomitant chronic plaque psoriasis treated with ustekinumab
Sir, Immunosuppressants and immunomodulators are the mainstay of treatment in systemic lupus erythematosus (SLE) and psoriasis. Ustekinumab, a monoclonal antibody against IL-12 and IL-23, has proven roles in psoriasis. In SLE, its efficacy has been demonstrated in a few cases. Acitretin is beneficial for psoriasis and has been used in SLE despite its photosensitizing potential. Phototherapy is effective in psoriasis; however, ultraviolet radiation is a well-known SLE exacerbating factor.
Ustekinumab has been used in the treatment of SLE following advances in research into the roles of IL-17 and IL-23 in its pathophysiology. A few cases of concomitant psoriasis, psoriatic arthropathy, and SLE have been successfully treated with ustekinumab. [1] [2] [3] Lupus nephritis was present in one case, 1 while both thrombocytopenia and autoimmune hemolytic anemia were present in another case. 2 The use of ustekinumab in SLE is promising. It would be a very useful treatment option in patients with coexisting SLE and psoriasis; however, contrary to the favorable reports on the efficacy of ustekinumab in CLE and SLE, we observed severe flares in our patient during ustekinumab therapy. The characteristics of patients who will most likely respond to treatment need to be delineated further. A single drug that is able to treat both psoriasis and SLE is desirable to minimize adverse reactions and cost. 
